

## Correction: *Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy*

Lee L, Lim WC, Galas-Filipowicz D, *et al.* Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy. *J ImmunoTher Cancer* 2023; **11**: e006699. doi: 10.1136/jitc-2023-006699

This article has been corrected since it was first published. Author name Kwee Yong has been corrected.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See <https://creativecommons.org/licenses/by/4.0/>.

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

*J ImmunoTher Cancer* 2023;**11**:e006699corr1. doi:10.1136/jitc-2023-006699corr1

